Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial

Por: Giaccone, G, Felip, E, Cobo, M, Campelo, RG, Denis, F, Quoix, E, Madroszyk, A, Debieuvre, D, Hilgers, W, Moran, T, Galetta, D, Romano, GD, Cappuzzo, F, Robinet, G, Masson, P, Viteri, S, Peled, N, Costantini, D, Dziadziuszko, R and Besse, B

---

Publicada: 1 sep 2020

---

---

Filiaciones:
Giaccone, G:
 Weill Cornell Med, Clin Res, New York, NY USA

Felip, E:
 Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

Cobo, M:
 Hosp Univ Reg & Virgen de la Victoria IBIMA, Unidad Gest Clin Intercentros Oncol Med, Malaga, Spain

Campelo, RG:
 Univ Hosp A Coruna, Med Oncol, La Coruna, Spain

Denis, F:
 Clin Victor Hugo Le Mans, Med Oncol, Le Mans, France

Quoix, E:
 Hop Univ Strasbourg, Nouvel Hop Civil, Pneumol Dept, Strasbourg, France

Madroszyk, A:
 Inst Paoli Calmettes, Med Oncol, Marseille, France

Debieuvre, D:
 Hop Emile Muller GHRMSA, Pneumol Dept, Mulhouse, France

Hilgers, W:
 Inst Ste Catherine, Med Oncol, Avignon, France

:
 Hosp Badalona Germans Trias & Pujol, ICO Badalona, B ARGO, Med Oncol, Barcelona, Spain

Galetta, D:
 Ist Tumori Giovanni Paolo II, Med Thorac Oncol Dept, Bari, Italy

Romano, GD:
 Osped Vito Fazzi, Dept Oncol, Lecce, Italy

Cappuzzo, F:
 AUSL Romagna, Department Oncol & Hematol, Ravenna, Italy

Robinet, G:
 CHU Brest, Hop Morvan, Med Oncol, Brest, France

Masson, P:
 Ctr Hosp Cholet, Pneumol Dept, Cholet, France

Viteri, S:
 Hosp Univ Dexeus, Inst Oncol Dr Rosell, Grp QuironSalud, Dept Oncol, Barcelona, Spain

Peled, N:
 Soroka Univ Med Ctr, Canc Ctr, Beer Sheva, Israel

Costantini, D:
 OSE Immunotherapeut, Dev, Paris, France

Dziadziuszko, R:
 Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland

Besse, B:
 Gustave Roussy, Med Oncol, Villejuif, France